Research programme: anti-TNF-alpha therapeutics - Pharmexa

Drug Profile

Research programme: anti-TNF-alpha therapeutics - Pharmexa

Alternative Names: Anti-TNFα vaccine - Pharmexa; Anti-tumour necrosis factor alpha vaccine - Pharmexa; AutoVac TNFα vaccine - Pharmexa; ME 101; PX 101; TNF-alpha AutoVac; TNFα AutoVac

Latest Information Update: 12 Apr 2006

Price : $50

At a glance

  • Originator Pharmexa
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Crohn's disease; Psoriasis; Rheumatoid arthritis
  • Discontinued Cachexia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Apr 2006 No development reported - Preclinical for Crohn's disease in Denmark (unspecified route)
  • 12 Apr 2006 No development reported - Preclinical for Psoriasis in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top